Results
102
Companys with strong funding and high growth potential
102 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 170.01 | -3.2% | -42.7% | SEK 14.9b | SEK 292.86 | PS49.8x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.20 | 5.3% | -25.0% | US$143.3m | US$8.65 | PS63.3x | E70.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €533.00 | -0.9% | 4.8% | €28.8b | €564.79 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
BIOABS | SEK 173.90 | 0% | n/a | SEK 14.9b | SEK 299.56 | PS49.8x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
ARDX | US$6.13 | -1.4% | 57.6% | US$1.4b | US$11.28 | PS6.9x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
ARGN.F | €525.60 | 0% | n/a | €28.8b | €556.95 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
0QW0 | €480.45 | -1.0% | 0.7% | €28.8b | €509.11 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
AKES.F | HK$8.48 | -9.8% | n/a | HK$56.7b | HK$8.48 | PS27.4x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €481.80 | -0.9% | 1.2% | €28.8b | €510.54 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 16.89 | -0.06% | -37.0% | SEK 14.9b | SEK 29.09 | PS49.8x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
BPMC | US$91.68 | 6.2% | 85.9% | US$5.8b | US$127.35 | PS16x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
0HOJ | US$92.67 | 7.0% | 85.0% | US$5.8b | US$128.73 | PS16x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$10.14 | -2.5% | 106.6% | US$3.1b | US$24.39 | PS94x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$22.00 | 0% | n/a | HK$69.5b | HK$30.07 | PS8.4x | E59.4% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$233.49 | 0.04% | 54.7% | US$5.1b | US$360.57 | PS346.3x | E68.1% | n/a | Pharmaceuticals & Biotech | ||
URGN | US$13.54 | 2.6% | -14.4% | US$570.2m | US$43.10 | PS6.7x | E55.1% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$5.89 | -0.3% | -4.2% | US$350.0m | US$10.00 | PB3.6x | E62.3% | n/a | Pharmaceuticals & Biotech | ||
ENSC | US$0.32 | -6.6% | -77.8% | US$3.5m | US$9.05 | PS2.5x | E96.3% | n/a | Pharmaceuticals & Biotech |